Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase NA 5Phase 2 3Phase 1/2 2Phase 4 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Breast Neoplasms 26Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Prostatic Neoplasms 8Multiple Myeloma 7Lung Neoplasms 7Melanoma 6Stomach Neoplasms 5Leukemia, Myeloid, Acute 5Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Sarcoma 3Papillomavirus Infections 3Neoplasm Metastasis 3Hematologic Neoplasms 3Glioblastoma 3Warts 2Venous Thromboembolism 2Thyroid Neoplasms 2Skin Neoplasms 2Rectal Neoplasms 2Polycythemia Vera 2Pain 2Ovarian Neoplasms 2Oligodendroglioma 2Obesity 2Neoplasms by Site 2Myasthenia Gravis 2

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Meningeal Carcinomatosis × 90 days × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡